It is proposed that this article be deleted because of the following concern:
If you can address this concern by improving, copyediting, sourcing, renaming, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it . The article may be deleted if this message remains in place for seven days, i.e., after 04:27, 29 October 2018 (UTC). Nominator: Please consider notifying the author/project: {{subst:proposed deletion notify |Enokizumab|concern=nothing on PubMed}} ~~~~ |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL9 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10000N1704O2038S44 |
| Molar mass | 148.4 kg/mol |
  | |
Enokizumab is a humanized monoclonal antibody designed for the treatment of asthma. [1]
Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person, they may become worse at night or with exercise.
Enokizumab was developed by MedImmune.
